Akansha Medicines Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 10-12-2024
- Paid Up Capital ₹ 0.15 M
as on 10-12-2024
- Company Age 19 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Profit 28.23%
(FY 2022)
- Ebitda 1.14%
(FY 2022)
- Net Worth -10.65%
(FY 2022)
- Total Assets -0.52%
(FY 2022)
About Akansha Medicines
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Rajiv Ranjan, Renuka Ranjan, and Pranao Bhushan serve as directors at the Company.
- CIN/LLPIN
U24232UP2005PTC030662
- Company No.
030662
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Sep 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Akansha Medicines?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Ranjan  | Director | 23-Sep-2005 | Current |
| Renuka Ranjan | Director | 27-Jun-2023 | Current |
| Pranao Bhushan | Director | 29-Mar-2013 | Current |
Financial Performance of Akansha Medicines.
Akansha Medicines Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 28.23% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Akansha Medicines?
In 2017, Akansha Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Akansha Dairy Private LimitedActive 19 years 2 monthsRajiv Ranjan, Renuka Ranjan and 1 more are mutual person
- Nyra Marketing LimitedActive 8 years 10 months
Rajiv Ranjan, Renuka Ranjan and 1 more are mutual person
- Akansha Jewel Export Private LimitedActive 19 years 2 months
Rajiv Ranjan, Renuka Ranjan and 1 more are mutual person
- Akansha Buildcon Private LimitedActive 19 years 2 months
Rajiv Ranjan, Renuka Ranjan and 1 more are mutual person
- Fortune Infrarealtors Private LimitedActive 13 years 10 months
Rajiv Ranjan, Renuka Ranjan and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Akansha Medicines?
Unlock and access historical data on people associated with Akansha Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Akansha Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Akansha Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
